Introduction
Multiparametric MRI (mpMRI) of the prostate plays an increasingly important role in prostate cancer diagnostics. An unsuspicious MRI has a high negative predictive value (NPV) for the detection of Gleason score ≥7 cancer on biopsy [1] [2] [3] [4] . International guidelines therefore currently recommend MRI of the prostate for men with previous negative biopsies and for staging purposes in patients with biopsy confirmed cancer [5] [6] [7] . The use of MRI/ultrasound (US) image-fusion promises to be useful in primary biopsy. Most importantly, the technique may provide more accurate primary risk stratification [8] [9] [10] . Localisation, extent, and Gleason score of cancer found in fusion biopsies correlate with the final result of radical prostatectomy (RP) specimens [11, 12] . Yet, MRI may miss Gleason score ≥7 cancer in 8-24% of patients when a RP specimen is used as the reference method [13] [14] [15] . There is conflicting evidence of as to whether targeted biopsies alone or a combination of targeted and systematic biopsies are the best approach, as well as controversy to the number of cores to take and the route [10, [15] [16] [17] [18] [19] [20] . Given the conflicting evidence to date, the aim of the present study was therefore to prospectively clarify the detection rates of targeted and systematic transperineal MRI/US image-fusion prostate biopsies in patients with previous negative transrectal biopsies using the data from two different tertiary referral centres.
Patients and Methods

Standards of Reporting
The Standards of Reporting for MRI-targeted Biopsy Studies (START) were used to describe the study population, the conduct and reporting of the MRI, the conduct of the biopsy, and the results [21] . The biopsy technique and data collection was prospectively standardised according to the Ginsburg consensus [22] .
Study Population
Patients with previous negative transrectal biopsies according to local standard without the diagnosis or treatment of prostate cancer were included in the evaluation. From October 2012 to November 2015, 287 patients underwent mpMRI and subsequent transperineal prostate biopsies in Centre 1, and 200 patients in Centre 2. None of the patients had previously undergone transperineal biopsy. The objective was to identify clinically significant cancer, defined as Gleason score 7-10. The final study cohort comprised 487 patients. The indication for repeat biopsy in the patients were either rising PSA values (404 patients) or a previous biopsy specimen showing suspicion of cancer (atypical small acinar proliferation) or multifocal high-grade prostatic intraepithelial neoplasia (83). The patients' clinical characteristics are shown in Table 1 .
Ethical Approval
All patients were counselled about the risks of the procedure and thereafter signed a consent form that included a permission to use their clinical data for research. The study was approved as a service evaluation by the local ethics and audit committees in both centres.
MRI
In Centre 1, all patients underwent prostate MRI on a 3.0-T Magnetom (Siemens, Erlangen, Germany) with the use of the manufacturer's standard multi-channel body coil and integrated spin phased-array coil, as previously described [15] . Patients in Centre 2 underwent prostate MRI on a 1.5-T MR450 (20 patients) or 3.0-T Discovery MR750 HDx (180 patients; GE Healthcare, Waukesha, USA) with an 8-16 channel surface phased-array coil as previously described [4] The MRI protocols are shown in Table S1 .
Image Analysis
The MRIs were read by at least one uro-radiologists with >3 years' experience of prostate MRI at a high-volume prostate cancer centre. All radiologists have ongoing histological feedback on >150 MRI/year. Images were analysed according to the Prostate Imaging-Reporting and Data System (PIRADS) version 1 [23] and a final score was defined by combining all three scores for T2-weighted, diffusion-weighted and dynamic contrast-enhanced imaging, respectively, according to criteria as described in PI-RADS version 2 [24] .
Biopsy
The Biopsee TM MRI/US-fusion biopsy system (Medcom, Darmstadt, Germany) was used for all biopsies. All men underwent volume-based systematic transperineal biopsies [25] . The final histology result of this specialist assessment was used as data for this study. According to the recently internationally accepted new prostate cancer grading system, adopted by the WHO in 2016, the clinically significant cancers as defined in this study as Gleason Score 7-10 would be equivalent to combined Grade Groups 2-5, with Gleason score 4 + 3 = 7 alone being Grade Group 3, and those Gleason Score 6 cancers regarded as clinically insignificant are equivalent to Grade Group 1 [26] .
Statistics
All data were collected prospectively in each centre. Descriptive statistics were used and positive (PPV) and negative (NPV) predictive values including 95% CIs were calculated, using the combined systematic transperineal biopsy AE targeted biopsies as reference test, which has been recently validated [15] . In addition, predictive values and detection rates were calculated for PSA densities of ≤0.15 and >0.15 ng/mL/mL. Detection rates of targeted and systematic cores were compared for each centre and combined. The McNemar test was used to test for statistical significance. Statistics was done using the Statistical Package for the Social Sciences (SPSS â ) Statistics 22 (IBM, Armonk, NY, USA).
Results
The distribution of MRI findings is shown in Table 2 . One or more lesion suspicious for cancer on MRI (PI-RADS 3-5) was found in 70% of the patients. The median [interquartile range (IQR)] number of target lesions was 1 (1-3). The median (IQR) number of targeted biopsy cores per patient was 3 (2-4) and the median (IQR) number of systematic cores was 24 (24) (25) (26) .
Prostate Cancer Detection, NPV and PPV of MRI
The biopsy results are shown in Table 3 . Gleason score 7-10 cancer was detected in 31% (149/487) of the patients. In all, 13/87 Gleason score 7-10 cancers in Centre 1 and 27/62 in Centre 2 were found exclusively in the anterior zone of the prostate, resulting in 27% clinically significant tumours. Nevertheless, the other 73% were found in areas supposedly representatively sampled previously by transrectal biopsies.
The systematic biopsies in the 144 patients with PI-RADS 1-2 MRI findings (i.e. with no suspicious lesion) detected cancer in 40 patients (28%), most of whom had Gleason score 6 cancer (29 patients). The NPV of PI-RADS 1-2 findings was 0.72 for excluding any cancer, 0.92 for excluding Gleason score 7-10 and 0.99 for excluding Gleason score ≥4 + 3 = 7 cancer (Table 4) , with no significant differences between the centres. Of 11 (8%) Gleason score 7-10 cancers Table 4 . Of 25 (20%) Gleason score 7-10 cancers in 128 patients with an equivocal PI-RADS 3 lesion on MRI, 13 (10%) were Gleason score 3 + 4, 9 (7%) were Gleason score 4 + 3, and 3 (2%) were Gleason score 8-10.
Combination of PI-RADS and PSA Density
Taking PSA density into account improved the predictive values of PI-RADS 3-5. The NPV of PI-RADS 1-2 findings for excluding Gleason score 7-10 cancer was 0.93 (79/85) for men with a PSA density of ≤0.15 ng/mL/mL and 0.92 (54/ 59) for men with a PSA density of >0.15 ng/mL/mL. PPVs were higher with rising PSA density, from 0.11 with a PSA density of ≤0.15 ng/mL/mL to 0.33 with a PSA density of >0.15 ng/mL/mL for PI-RADS 3 lesions, and from 0.33 with a PSA density of ≤0.15 ng/mL/mL to 0.65 with a PSA density of >0.15 ng/mL/mL 3 for PI-RADS 4-5 lesions (Table 5 ). The area under the curve (AUC) for the two density groups alone was 0.674 and for PI-RADS alone was 0.822. The combination of both improved the AUC to 0.846, which is significant compared to PI-RADS alone (P = 0.046; Fig. 1 ).
Comparison of Detection Rates in Targeted and Systematic Cores
Systematic biopsies in patients with PI-RADS 3-5 lesions on MRI did not detect 13/138 significant prostate cancers, with two Gleason score 3 + 4 and 11 Gleason score 4 + 3. Targeted biopsies of PI-RADS 3-5 lesions alone failed to diagnose 24/138 significant prostate cancers, with eight Gleason score 3 + 4, 12 Gleason score 4 + 3, and four Gleason score 8-10. A combination of targeted and systematic biopsies was significantly better than either method alone for the detection of significant Gleason score 7-10 cancer (P < 0.001; ( Table 6 ). Systematic biopsies alone in patients with suspicious lesions (PI-RADS 4-5) on MRI would not have detected 12/113 significant prostate cancers (P = 0.002), while performing only targeted biopsies of suspicious lesions would have failed to diagnose 10/113 significant prostate cancers (P = 0.004). In equivocal lesions (PI-RADS 3), targeted biopsy alone would not have diagnosed 14/25 Gleason score 7-10 cancers, whereas performing only systematic biopsies would have only missed 1/25 Gleason score 4 + 3, with no significant difference in detection rate between systematic and combined biopsy (P = 1.000). Table 4 The NPVs and PPVs of mpMRI using a transperineal MRI/US-fusion guided targeted and 24-core systematic prostate biopsy as the reference test.
Overall (N = 487)
Centre 1 (N = 287) 
Discussion
The present study reports the largest series of MRI/US imagefusion guided transperineal prostate biopsies in patients with previous negative transrectal biopsies, with the advantage of a multicentre comparison based on a prospectively standardised technique and data collection to evaluate the introduction of the use of MRI-based diagnostics in our centres.
Despite previous negative conventional transrectal biopsies, 51% of patients had cancer in the transperineal MRI/US-fusion biopsy and 31% had clinically significant disease; 73% of Gleason score 7-10 cancers were found in the previously sampled mid-to-posterior zone of the prostate. With a suspicious MRI (PI-RADS 4-5) detection rates rose to 71% for any cancer and to 53% with Gleason score 7-10. With an unsuspicious MRI (PI-RADS 1-2) the NPV for excluding Gleason score 7-10 cancer was 92%, using systematic transperineal saturation biopsy as the reference test. Our present results suggest that in men without suspicious lesions on highquality MRI, biopsy might be omitted altogether, and replicate the high NPVs that have been repeatedly published previously [4, 17, 19, 27, 28] . In our present study, 11 (8%) Gleason score 7-10 cancers in 144 patients with PI-RADS 1-2 MRI would have remained undiagnosed, only 1/11 being a Gleason score ≥4 + 3, Table 5 The detection rates of transperineal MRI/US-fusion guided targeted and 24-core systematic prostate biopsy depending on PSA density.
Overall (n = 487) Centre 1 (n = 287) Centre 2 (n = 200) whilst sparing 144 men (30%) a repeat biopsy. By adding a PSA density threshold, it may be possible to further increase the NPV of mpMRI [29] . In our present study, the NPV of MRI for men with a PSA density of <0.15 ng/mL/mL was 0.93, with five Gleason score 3 + 4 and one Gleason score 8.
The combination of targeted and systematic biopsies was significantly superior to either method alone for the detection of significant Gleason score 7-10 cancer (P < 0.001). The present multicentre result complements previous results from Radtke et al. [15] in RP patients. Several other studies have compared MRI/US-fusion targeted biopsy to systematic USguided biopsy with diverging results depending on type of systematic biopsy used or number of cores taken: Some found that MRI/US-fusion targeted biopsy led to increased detection of high-risk cancer and decreased detection of low-risk cancer but missed up to 6% of higher risk tumours [10, 17, 30, 31] ; others found similar detection rates in systematic and targeted transrectal biopsies [18, 32] .
In patients with equivocal lesions (PI-RADS 3), there was no significant difference between systematic biopsies alone and the combination of both targeted and systematic biopsy methods (P = 1.000). Systematic biopsies alone would have missed only 1/25 (4%) Gleason score 7-10 cancers, whereas targeted biopsy alone would not have diagnosed 14/25 (56%). These results suggest that the confidence of our radiologist to call the visible lesion significant (PIRADS 4 instead of 3) was clearly and rightly low, which is proven by the fact that the addition of targeted biopsy does not add value to systematic biopsies in this group. Work is needed to distinguish these equivocal lesions further into 'insignificant' and 'significant'. When counselling such patients whether or not and how to undergo repeat biopsy, urologists should include clinical risk factors like PSA level and PSA density. In present our study, equivocal (PIRADS 3) lesions on MRI in patients with a low PSA density had a NPV of 0.89. Proceeding without biopsy can be considered for such patients with follow-up in place.
For suspicious lesions (PI-RADS 4-5), both biopsy methods alone were inferior to the combination of both (P < 0.001), but systematic biopsies missed more significant prostate cancer (12/113) than targeted biopsies (10/113). These results stress the need to improve the technique of targeted biopsies before an omission of systematic biopsies in patients with suspicious MRI can be taken into further consideration. Failure to detect significant cancer in targeted biopsies may have several explanations: communication of reports between radiology and urology, patient factors, fusion-technique, and biopsy core number, can all affect the accuracy of cancer detection. Additionally, patient positioning, breathing movements, and deformation of the prostate gland during the biopsy procedure can lead to incorrect fusion of previously acquired MRI images and real-time US, despite using software registration, general anaesthesia, and experienced operators. A way to overcome these limitations would be the use of 'saturation' target cores, with more cores per lesion to improve detection rates. For this reason, Centre 1 had started to take a minimum of ≥4 targeted biopsies per lesion (Fig. 2) towards the end of the study period and Centre 2 since analysis of joint data was available.
A strength of our present study is that we prospectively collected data on a repeat biopsy population in a multicentre setting using a combination of targeted and systematic transperineal saturation biopsy as the reference. Next to RP specimens and transperineal mapping, this is the most valid means of assessing for clinically significant prostate cancer, especially in a patient population in which not all patients need to undergo RP.
Our present study has several limitations. Despite prospective collection of data, the analysis was performed retrospectively. Therefore, MRI readings were conducted prospectively according to PI-RADS version 1 with a final combined score, according to criteria as later described in PI-RADS version 2, even before its introduction. Therefore, the results given in Table 6 The detection rates of transperineal MRI/US-fusion guided targeted and 24-core systematic prostate biopsy for significant Gleason score 7-10 prostate cancer.
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Centre 1 (n = 287) Centre 2 (n = 200) N Detection rates, % P N Detection rates % P N Detection rates % P this manuscript reflect a mix of both PI-RADS versions, as in the clinical reality in the turn-over period. Our present results cannot necessarily be applied to patients without previous biopsies. We do not know if any patients underwent MRI before the initial transrectal biopsy, as most of them were external referrals. As Radtke et al. [19] and Hansen et al. [4] demonstrated, first biopsy patients are more likely to have higher predictive values in transperineal MRI/US-fusion biopsy than patients with previous negative transrectal biopsies. Also, the high cancer detection rate in systematic cores could be influenced by the fact that these also included the cores from the sector where a target was found, resulting in a possible bias to re-sampling the targets as urologists were not blinded to them. We also acknowledge that the parameter of Gleason score 7-10 cancer, as the definition of 'clinically significant' cancer is debatable. Our present analysis has not taken into account the amount of large volume Gleason score 6 or small volume Gleason score 3 + 4. The incorporation of cancer volume via the number of infiltrated cores and the maximum cancer core length is currently being incorporated into clinical practice.
Conclusion
In patients with high probability MRI lesions, the highest detection rates of Gleason score 7-10 cancer still required combined targeted and systematic MRI/US-fusion biopsy; however, systematic biopsy alone may be sufficient in patients with equivocal lesions. Repeated prostate biopsies may not be needed at all for patients with a low PSA density and a negative MRI read by experienced radiologists.
